Shunji Narumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shunji Narumi has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Kenta Futamura
11 shared publications- Yoshihiko Watarai
Department of Kidney Disease Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan
9 shared publications - Manabu Okada
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
8 shared publications - Takahisa Hiramitsu
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
7 shared publications Asami Takeda
6 shared publicationsNorihiko Goto
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Department of Transplant and Endocrine Surgery, 2-9 Myoken-cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan
5 shared publications
Latest Publications
- 12 June 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 35-39
Thrombotic Microangiopathy in Renal Allograft Induced by Valproic Acid Treatment in Addition to Tacrolimus and Everolimus: A Case Report
Introduction: Thrombotic microangiopathy (TMA) is a known complication in renal transplant recipients and is often associated with drugs like calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors. Additionally, toxic levels of valproic acid have been implicated in systemic TMA. This report describes a case of pathologic TMA in a renal allograft that may be induced by the combined use of CNI, mTOR inhibitor, and valproic acid at standard doses. Case Presentation: A 37-year-old female diagnosed with glomerulonephritis underwent ABO-compatible living donor renal transplantation. Following the procedure, the blood concentrations of tacrolimus (CNI) and everolimus (mTOR inhibitor) were maintained at optimal levels. Two and a half years posttransplant, valproic acid therapy was initiated for migraine management and titrated within the therapeutic range. Despite the gradual decline in renal function, there was no evidence of anemia or thrombocytopenia. Four years posttransplant, a graft biopsy identified a necrotic thrombotic microvascular lesion suggestive of acute TMA, despite no signs of rejection. Renal function stabilized after the discontinuation of valproic acid. Conclusion: Pathological TMA may impair renal function in patients receiving multiple drugs known to induce TMA. Hence, an early graft biopsy may be crucial for diagnosis, even when blood levels of immunosuppressive drugs are within the therapeutic range.
- 12 June 2025
- Published by S. Karger AG in Nephron
- Vol. 149 (Suppl. 1) , 35-39
Thrombotic Microangiopathy in Renal Allograft Induced by Valproic Acid Treatment in Addition to Tacrolimus and Everolimus: A Case Report
Introduction: Thrombotic microangiopathy (TMA) is a known complication in renal transplant recipients and is often associated with drugs like calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors. Additionally, toxic levels of valproic acid have been implicated in systemic TMA. This report describes a case of pathologic TMA in a renal allograft that may be induced by the combined use of CNI, mTOR inhibitor, and valproic acid at standard doses. Case Presentation: A 37-year-old female diagnosed with glomerulonephritis underwent ABO-compatible living donor renal transplantation. Following the procedure, the blood concentrations of tacrolimus (CNI) and everolimus (mTOR inhibitor) were maintained at optimal levels. Two and a half years posttransplant, valproic acid therapy was initiated for migraine management and titrated within the therapeutic range. Despite the gradual decline in renal function, there was no evidence of anemia or thrombocytopenia. Four years posttransplant, a graft biopsy identified a necrotic thrombotic microvascular lesion suggestive of acute TMA, despite no signs of rejection. Renal function stabilized after the discontinuation of valproic acid. Conclusion: Pathological TMA may impair renal function in patients receiving multiple drugs known to induce TMA. Hence, an early graft biopsy may be crucial for diagnosis, even when blood levels of immunosuppressive drugs are within the therapeutic range.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 15 (1) , 98-104
Clinical and Pathological Course of Recurrent C3 Glomerulonephritis from Onset to Graft Loss: A Case Report
Introduction: Complement 3 glomerulonephritis (C3GN) has a high recurrence rate after kidney transplantation. Before the disease became well understood, kidney transplantation was performed without a diagnosis of C3GN. This report describes a case of recurrent C3GN diagnosed using allograft biopsy and evaluates its long-term clinical and pathological course. Case Presentation: A 35-year-old man with membranoproliferative glomerulonephritis underwent an ABO-compatible living-donor renal transplantation. Three weeks post-transplantation, an allograft biopsy showed prominent granular C3 deposits. One year after transplantation, an allograft biopsy revealed slight mesangial expansion with C3 deposits and a few urinary proteins. Recurrent C3GN was diagnosed based on similar C3 deposition in the native kidney. Eight years post-transplantation, urinary protein levels began to increase and renal function gradually declined. Approximately 10 years after transplantation, an allograft biopsy revealed severe secondary focal segmental glomerulosclerosis and arteriolopathy with no active C3GN lesions. Ten months later, deteriorating kidney function necessitated hemodialysis. Conclusion: In this case, C3GN recurred early after transplantation, but its activity did not increase for 8 years. The causes of chronic allograft dysfunction vary among cases. More cases and detailed observational studies are needed to determine treatment strategies for recurrent C3GN and graft prognosis.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 15 (1) , 98-104
Open AccessClinical and Pathological Course of Recurrent C3 Glomerulonephritis from Onset to Graft Loss: A Case Report
Introduction: Complement 3 glomerulonephritis (C3GN) has a high recurrence rate after kidney transplantation. Before the disease became well understood, kidney transplantation was performed without a diagnosis of C3GN. This report describes a case of recurrent C3GN diagnosed using allograft biopsy and evaluates its long-term clinical and pathological course. Case Presentation: A 35-year-old man with membranoproliferative glomerulonephritis underwent an ABO-compatible living-donor renal transplantation. Three weeks post-transplantation, an allograft biopsy showed prominent granular C3 deposits. One year after transplantation, an allograft biopsy revealed slight mesangial expansion with C3 deposits and a few urinary proteins. Recurrent C3GN was diagnosed based on similar C3 deposition in the native kidney. Eight years post-transplantation, urinary protein levels began to increase and renal function gradually declined. Approximately 10 years after transplantation, an allograft biopsy revealed severe secondary focal segmental glomerulosclerosis and arteriolopathy with no active C3GN lesions. Ten months later, deteriorating kidney function necessitated hemodialysis. Conclusion: In this case, C3GN recurred early after transplantation, but its activity did not increase for 8 years. The causes of chronic allograft dysfunction vary among cases. More cases and detailed observational studies are needed to determine treatment strategies for recurrent C3GN and graft prognosis.
- Open Access
- 15 October 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 413-415
A novel technique for pancreatic-juice drainage to the remaining graft duodenum after blood reperfusion in pancreas transplantation
- 15 October 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 413-415
Open AccessA novel technique for pancreatic-juice drainage to the remaining graft duodenum after blood reperfusion in pancreas transplantation
- Open Access
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1175237
Maximal parathyroid gland diameter as a predictive factor for autograft-dependent recurrent secondary hyperparathyroidism after total parathyroidectomy
Introduction: Following total parathyroidectomy (PTx), transcervical thymectomy, and forearm autograft for secondary hyperparathyroidism (SHPT), recurrent SHPT can occur in the autografted forearm. However, few studies have investigated the factors contributing to re-PTx due to autograft-dependent recurrent SHPT before the completion of the initial PTx.Methods: A total of 770 patients who had autografted parathyroid fragments derived from only one of the resected parathyroid glands (PTGs) and who had undergone successful initial total PTx and transcervical thymectomy—defined by serum intact parathyroid hormone level < 60 pg/mL on postoperative day 1—between January 2001 and December 2022 were included in this retrospective cohort study. Factors contributing to re-PTx due to graft-dependent recurrent SHPT before the completion of the initial PTx were investigated using multivariate Cox regression analysis. Receiver operating characteristic (ROC) curve analysis was performed to obtain the optimal maximum diameter of PTG for autograft.Results: Univariate analysis showed that dialysis vintage and maximum diameter and weight of the PTG for autograft were significant factors contributing to graft-dependent recurrent SHPT. However, multivariate analysis revealed that dialysis vintage (P=0.010; hazard ratio [HR], 0.995; 95% confidence interval [CI], 0.992–0.999) and the maximum diameter of the PTG for autograft (P=0.046; HR, 1.107; 95% CI, 1.002–1.224) significantly contributed to graft-dependent recurrent SHPT. ROC curve analysis showed that < 14 mm was the optimal maximum diameter of PTG for autograft (area under the curve, 0.628; 95% CI, 0.551–0.705).Conclusions: The dialysis vintage and maximum diameter of PTG for autograft may contribute to re-PTx due to autograft-dependent recurrent SHPT, which can be prevented by using PTGs with a maximum diameter of < 14 mm for autograft.
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1175237
Open AccessMaximal parathyroid gland diameter as a predictive factor for autograft-dependent recurrent secondary hyperparathyroidism after total parathyroidectomy
Introduction: Following total parathyroidectomy (PTx), transcervical thymectomy, and forearm autograft for secondary hyperparathyroidism (SHPT), recurrent SHPT can occur in the autografted forearm. However, few studies have investigated the factors contributing to re-PTx due to autograft-dependent recurrent SHPT before the completion of the initial PTx.Methods: A total of 770 patients who had autografted parathyroid fragments derived from only one of the resected parathyroid glands (PTGs) and who had undergone successful initial total PTx and transcervical thymectomy—defined by serum intact parathyroid hormone level < 60 pg/mL on postoperative day 1—between January 2001 and December 2022 were included in this retrospective cohort study. Factors contributing to re-PTx due to graft-dependent recurrent SHPT before the completion of the initial PTx were investigated using multivariate Cox regression analysis. Receiver operating characteristic (ROC) curve analysis was performed to obtain the optimal maximum diameter of PTG for autograft.Results: Univariate analysis showed that dialysis vintage and maximum diameter and weight of the PTG for autograft were significant factors contributing to graft-dependent recurrent SHPT. However, multivariate analysis revealed that dialysis vintage (P=0.010; hazard ratio [HR], 0.995; 95% confidence interval [CI], 0.992–0.999) and the maximum diameter of the PTG for autograft (P=0.046; HR, 1.107; 95% CI, 1.002–1.224) significantly contributed to graft-dependent recurrent SHPT. ROC curve analysis showed that < 14 mm was the optimal maximum diameter of PTG for autograft (area under the curve, 0.628; 95% CI, 0.551–0.705).Conclusions: The dialysis vintage and maximum diameter of PTG for autograft may contribute to re-PTx due to autograft-dependent recurrent SHPT, which can be prevented by using PTGs with a maximum diameter of < 14 mm for autograft.
- Open Access
- 21 February 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 96-100
Light Chain Deposition Disease Recurrence in Renal Allograft after Long-Term Remission
Light chain deposition disease (LCDD) is a rare manifestation of monoclonal gammopathy, which can lead to renal failure. We previously reported a detailed recurrence process in a case of LCDD after renal transplantation. To the best of our knowledge, no report has described the long-term clinical course and renal pathology findings of recurrent LCDD in patients after renal transplantation. In this case report, we describe the long-term clinical presentation and changes in renal pathology of the same patient after early LCDD relapse in a renal allograft. A 54-year-old woman with recurrent immunoglobulin A λ-type LCDD in an allograft was admitted 1 year post-transplant for bortezomib and dexamethasone therapy. At 2 years post-transplantation, a graft biopsy performed after complete remission was achieved, showing some glomeruli with residual nodular lesions similar to the pre-treatment renal biopsy findings. However, the enlarged subendothelial space disappeared. She remained in complete remission serologically for 6 years. Subsequently, the ratio of serum κ/λ-free light chains decreased gradually. She underwent a transplant biopsy approximately 12 years after renal transplantation due to increased proteinuria and decreased renal function. Compared with the previous graft biopsy, almost all glomeruli showed advanced nodule formation and subendothelial expansion. Because the LCDD case relapsed after long-term remission following renal transplantation, protocol biopsy monitoring might be necessary.
- 21 February 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 96-100
Open AccessLight Chain Deposition Disease Recurrence in Renal Allograft after Long-Term Remission
Light chain deposition disease (LCDD) is a rare manifestation of monoclonal gammopathy, which can lead to renal failure. We previously reported a detailed recurrence process in a case of LCDD after renal transplantation. To the best of our knowledge, no report has described the long-term clinical course and renal pathology findings of recurrent LCDD in patients after renal transplantation. In this case report, we describe the long-term clinical presentation and changes in renal pathology of the same patient after early LCDD relapse in a renal allograft. A 54-year-old woman with recurrent immunoglobulin A λ-type LCDD in an allograft was admitted 1 year post-transplant for bortezomib and dexamethasone therapy. At 2 years post-transplantation, a graft biopsy performed after complete remission was achieved, showing some glomeruli with residual nodular lesions similar to the pre-treatment renal biopsy findings. However, the enlarged subendothelial space disappeared. She remained in complete remission serologically for 6 years. Subsequently, the ratio of serum κ/λ-free light chains decreased gradually. She underwent a transplant biopsy approximately 12 years after renal transplantation due to increased proteinuria and decreased renal function. Compared with the previous graft biopsy, almost all glomeruli showed advanced nodule formation and subendothelial expansion. Because the LCDD case relapsed after long-term remission following renal transplantation, protocol biopsy monitoring might be necessary.
- Open Access
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S281
Angioplasty or sacrifice is better in multiple renal artery grafts: a computed tomography image analysis study
Taiki Ogasa, Yuki Nakagawa, Shuji Isotani, Kenta Futamura, Manabu Okada, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai. Korean J Transplant 2022;36:281. https://doi.org/10.4285/ATW2022.F-4242
- 17 November 2022
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 36 (1) , S281
Open AccessAngioplasty or sacrifice is better in multiple renal artery grafts: a computed tomography image analysis study
Taiki Ogasa, Yuki Nakagawa, Shuji Isotani, Kenta Futamura, Manabu Okada, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai. Korean J Transplant 2022;36:281. https://doi.org/10.4285/ATW2022.F-4242
- Open Access
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S105
235.6: The Impact of Extended Release Tacrolimus and Everolimus Based Immunosuppressive Regimen on Living Donor Kidney Transplantation
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S105
Open Access235.6: The Impact of Extended Release Tacrolimus and Everolimus Based Immunosuppressive Regimen on Living Donor Kidney Transplantation
- 31 March 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (6) , e14655
Two‐year outcomes of low‐exposure extended‐release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi‐center randomized controlled trial
Background: Once‐daily extended‐release tacrolimus (TACER) is commonly administered following kidney transplantation (KTx); however, its optimal dosage remains unknown.Methods: In this multi‐center, randomized controlled trial, 62 living donor KTx recipients were assigned to either standard‐exposure (SE; n = 32) or low‐exposure (LE; n = 30) TACER (Graceptor®, Astellas Pharm Inc.) groups. All patients received basiliximab and mycophenolate mofetil (MMF). The primary outcomes were acute rejection, graft/patient survival, and the secondary outcomes were incidence of cytomegalovirus infection, and de novo donor‐specific antibodies (dnDSA) production.Results: The tacrolimus trough level and estimated area under the blood concentration–time curve (eAUC) were significantly higher in SE than in LE (SE vs. LE; 1 year: 5.0 ± 0.9 ng/ml and 206.9 ± 26.8 ng h/ml vs. 3.4 ± 1.0 ng/ml and 153.9 ± 26.4 ng h/ml; 2 years: 4.8 ± 1.0 ng/ml and 204.9 ± 30.1 ng h/ml vs. 3.8 ± 0.9 ng/ml and 164.4 ± 27.0 ng h/ml). In contrast, the dosage and eAUC of MMF did not differ between groups. Two‐year graft and patient survival rates were 100% in both groups, and acute rejection rates were 0% and 10% in the SE and LE, respectively (p = 0.11). The mean estimated glomerular filtration rates did not differ between the groups. Cytomegalovirus infection was slightly lower in the LE (SE: 12.5% and LE: 6.7%, p = 0.37). In the LE, four cases of dnDSA were noted within 2 years of transplantation; no case was observed in the SE (p = 0.034).Conclusions: Although the LE TACER regimen showed similar rates of acute rejection, as well as graft and patient survival compared with SE after KTx, LE was significantly more associated with dnDSA. Further investigation of its long‐term effect on graft survival is warranted. (University Hospital Medical Information Network Clinical Trials Registry ID: UMIN000033089).
- 31 March 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (6) , e14655
Two‐year outcomes of low‐exposure extended‐release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi‐center randomized controlled trial
Background: Once‐daily extended‐release tacrolimus (TACER) is commonly administered following kidney transplantation (KTx); however, its optimal dosage remains unknown.Methods: In this multi‐center, randomized controlled trial, 62 living donor KTx recipients were assigned to either standard‐exposure (SE; n = 32) or low‐exposure (LE; n = 30) TACER (Graceptor®, Astellas Pharm Inc.) groups. All patients received basiliximab and mycophenolate mofetil (MMF). The primary outcomes were acute rejection, graft/patient survival, and the secondary outcomes were incidence of cytomegalovirus infection, and de novo donor‐specific antibodies (dnDSA) production.Results: The tacrolimus trough level and estimated area under the blood concentration–time curve (eAUC) were significantly higher in SE than in LE (SE vs. LE; 1 year: 5.0 ± 0.9 ng/ml and 206.9 ± 26.8 ng h/ml vs. 3.4 ± 1.0 ng/ml and 153.9 ± 26.4 ng h/ml; 2 years: 4.8 ± 1.0 ng/ml and 204.9 ± 30.1 ng h/ml vs. 3.8 ± 0.9 ng/ml and 164.4 ± 27.0 ng h/ml). In contrast, the dosage and eAUC of MMF did not differ between groups. Two‐year graft and patient survival rates were 100% in both groups, and acute rejection rates were 0% and 10% in the SE and LE, respectively (p = 0.11). The mean estimated glomerular filtration rates did not differ between the groups. Cytomegalovirus infection was slightly lower in the LE (SE: 12.5% and LE: 6.7%, p = 0.37). In the LE, four cases of dnDSA were noted within 2 years of transplantation; no case was observed in the SE (p = 0.034).Conclusions: Although the LE TACER regimen showed similar rates of acute rejection, as well as graft and patient survival compared with SE after KTx, LE was significantly more associated with dnDSA. Further investigation of its long‐term effect on graft survival is warranted. (University Hospital Medical Information Network Clinical Trials Registry ID: UMIN000033089).
- 30 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 86-90
Study of Glomerulopathy in Donors after Kidney Transplantation
Introduction: Living kidney donation improves the lives of individuals with kidney failure; however, recent studies have suggested that living kidney donors may be at a relatively higher risk of reduced renal function than healthy non-donors. We therefore aimed to evaluate the clinical and pathological findings in living kidney donors who developed kidney disease. Methods: From January 1991 to May 2019, 1,625 live kidney donations were performed at our hospital. Among the donors, 7 developed kidney disease after donation and underwent open renal biopsy. We studied the clinical and pathological findings of these patients from their clinical records. Results: There were 3 patients with immunoglobulin A (IgA) nephropathy, 2 with membranous nephropathy, 1 with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis, and 1 with secondary focal segmental glomerulosclerosis (FSGS). All patients with IgA nephropathy had latent IgA deposition on their baseline biopsy. One patient with membranous nephropathy demonstrated findings of membranous nephropathy on the baseline biopsy, despite being asymptomatic. All patients, except for those with ANCA-associated nephropathy and secondary FSGS, recovered from the nephritis or maintained an adequate renal function after treatment. Discussion/Conclusion: Baseline biopsy is necessary for assessing the renal condition of kidney donors, and these donors require long-term follow-up based on their baseline biopsy findings. If donors develop kidney disease, appropriate diagnosis and treatment are essential.
- 30 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 86-90
Study of Glomerulopathy in Donors after Kidney Transplantation
Introduction: Living kidney donation improves the lives of individuals with kidney failure; however, recent studies have suggested that living kidney donors may be at a relatively higher risk of reduced renal function than healthy non-donors. We therefore aimed to evaluate the clinical and pathological findings in living kidney donors who developed kidney disease. Methods: From January 1991 to May 2019, 1,625 live kidney donations were performed at our hospital. Among the donors, 7 developed kidney disease after donation and underwent open renal biopsy. We studied the clinical and pathological findings of these patients from their clinical records. Results: There were 3 patients with immunoglobulin A (IgA) nephropathy, 2 with membranous nephropathy, 1 with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis, and 1 with secondary focal segmental glomerulosclerosis (FSGS). All patients with IgA nephropathy had latent IgA deposition on their baseline biopsy. One patient with membranous nephropathy demonstrated findings of membranous nephropathy on the baseline biopsy, despite being asymptomatic. All patients, except for those with ANCA-associated nephropathy and secondary FSGS, recovered from the nephritis or maintained an adequate renal function after treatment. Discussion/Conclusion: Baseline biopsy is necessary for assessing the renal condition of kidney donors, and these donors require long-term follow-up based on their baseline biopsy findings. If donors develop kidney disease, appropriate diagnosis and treatment are essential.
- 25 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 49-53
A Case of Recurrent Atypical Anti-Glomerular Basement Membrane Nephritis Suspicion after Renal Transplantation
Atypical anti-glomerular basement membrane (GBM) nephritis is a rare variant of the classical anti-GBM antibody disease. Patients present with an undetectable anti-GBM antibody but show linear glomerular basement membrane staining for immunoglobulin. We present a 69-year-old man who underwent a living-donor kidney transplant. The aetiology of the renal failure was a focal segmental glomerulonephritis-like lesion resistant to immunosuppressive therapy. A renal graft biopsy revealed diffuse endocapillary hypercellularity, and mild mesangiolysis with linear GBM staining for IgG. The patient was diagnosed with atypical anti-GBM nephritis since the patient tested negative for circulating anti-GBM antibodies. Treatment involved intravenous methylprednisolone, plasma exchange, and rituximab administration. Protocol graft biopsy performed 1 year after the renal transplant showed a focal segmental glomerulonephritis-like lesion possibly progressing from endocapillary hypercellularity and mesangiolysis. These findings were similar to his native kidney biopsy findings. Although classical recurrent anti-GBM nephritis is rare when a renal transplant is performed after decreased disease activity, this case was considered as a case of recurrent atypical anti-GBM nephritis after renal transplant.
- 25 November 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (Suppl. 1) , 49-53
A Case of Recurrent Atypical Anti-Glomerular Basement Membrane Nephritis Suspicion after Renal Transplantation
Atypical anti-glomerular basement membrane (GBM) nephritis is a rare variant of the classical anti-GBM antibody disease. Patients present with an undetectable anti-GBM antibody but show linear glomerular basement membrane staining for immunoglobulin. We present a 69-year-old man who underwent a living-donor kidney transplant. The aetiology of the renal failure was a focal segmental glomerulonephritis-like lesion resistant to immunosuppressive therapy. A renal graft biopsy revealed diffuse endocapillary hypercellularity, and mild mesangiolysis with linear GBM staining for IgG. The patient was diagnosed with atypical anti-GBM nephritis since the patient tested negative for circulating anti-GBM antibodies. Treatment involved intravenous methylprednisolone, plasma exchange, and rituximab administration. Protocol graft biopsy performed 1 year after the renal transplant showed a focal segmental glomerulonephritis-like lesion possibly progressing from endocapillary hypercellularity and mesangiolysis. These findings were similar to his native kidney biopsy findings. Although classical recurrent anti-GBM nephritis is rare when a renal transplant is performed after decreased disease activity, this case was considered as a case of recurrent atypical anti-GBM nephritis after renal transplant.